SOD1 plasma level as a biomarker for therapeutic failure in cutaneous leishmaniasis.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 24511100.
- Also identified by DOI 10.1093/infdis/jiu087 and PMC identifier 4073785.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We show that increased plasma superoxide dismutase 1 (SOD1) levels are statistically significant predictors of the failure of pentavalent antimony treatment for cutaneous leishmaniasis caused by Leishmania braziliensis. In Leishmania amazonensis-infected patients, host SOD1 levels can be used to discriminate between localized and drug-resistant diffuse cutaneous leishmaniasis. Using in situ transcriptomics (nCounter), we demonstrate a significant positive correlation between host SOD1 and interferon α/β messenger RNA (mRNA) levels, as well as interkingdom correlation between host SOD1 and parasite SOD2/4 mRNA levels. In human macrophages, in vitro treatment with SOD1 increases the parasite burden and induces a diffuse cutaneous leishmaniasis-like morphology. Thus, SOD1 is a clinically relevant biomarker and a therapeutic target in both localized and diffuse cutaneous leishmaniasis.
Medical subject headings
- Antimony
- Antiprotozoal Agents
- Biomarkers
- Leishmania braziliensis
- Leishmaniasis, Cutaneous
- Superoxide Dismutase